# Palisade Bio, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Palisade Bio, Inc). ## Overview Palisade Bio, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing therapeutic product candidates for gastrointestinal and inflammatory diseases. Its lead program, PALI-2108, is being advanced through preclinical and clinical development with external research, manufacturing, and regulatory partners. ## Products & services • PALI-2108 therapeutic product candidate • Clinical-stage drug development • Preclinical and Phase 1 trial execution • Regulatory and commercialization preparation - **Lead therapeutic candidate** (100%) — PALI-2108 is the company's lead drug candidate for gastrointestinal and inflammatory indications. - **Clinical development services** (0%) — Internal and outsourced activities to advance PALI-2108 through trials and regulatory steps. - **Research collaboration and licensing** (0%) — Development rights and collaboration arrangements tied to the PALI-2108 program. - PALI-2108 therapeutic product candidate - Clinical-stage drug development - Preclinical and Phase 1 trial execution - Regulatory and commercialization preparation ## Customers Palisade Bio does not sell commercial products today; its primary counterparties are clinical trial participants, investigators, contract research organizations, contract manufacturers, and regulatory agencies. If approved in the future, its end customers would be physicians, insurers, payors, and patients in the gastrointestinal disease market. - **Clinical research partners** (primary) — Investigators, CROs, and trial sites that execute and oversee PALI-2108 studies. - **Manufacturing and supply partners** (primary) — API suppliers and third-party manufacturers that produce clinical trial materials. - **Regulatory authorities** (primary) — Health Canada, FDA, and other agencies that review trial and product approvals. - **Future healthcare buyers** (emerging) — Physicians, insurers, payors, and patients who would adopt PALI-2108 if commercialized. - Clinical trial sites and investigators running PALI-2108 studies - CROs managing trial operations, monitoring, and data collection - Contract manufacturers supplying API and clinical materials - Regulators such as Health Canada and the FDA - Future physicians, payors, and patients if the drug is approved ## Geography The company is headquartered in the United States and conducts its development activities through a cross-border clinical footprint. Its current clinical work includes studies in Canada, with planned U.S. clinical development subject to FDA clearance, which makes regulatory timing and trial execution in both countries strategically important. - United States headquarters and planned U.S. clinical development - Canada-based clinical studies for the Phase 1 program - FDA and Health Canada are key regulatory touchpoints - Cross-border trial setup affects timing, data acceptance, and cost ## Strategy Palisade Bio's strategy is to advance PALI-2108 through clinical development, generate regulatory data, and position the asset for later-stage development and potential commercialization. The company relies on external partners for manufacturing and clinical operations, while preserving capital through collaboration, licensing, and financing activities. - **Complete clinical development of PALI-2108** (short-term) — Clinical proof-of-concept is the main value driver for a single-asset biotech. - **Maintain outsourced manufacturing and trial execution** (short-term) — The company depends on third parties for API supply, trial conduct, and cGMP production. - **Secure regulatory and financing runway** (medium-term) — Development programs require approvals and capital before any commercial revenue exists. - Advance PALI-2108 through Phase 1 and later-stage trials - Use CROs and contract manufacturers instead of internal production - Secure regulatory approvals in Canada and the United States - Preserve optionality through collaborations and licensing - Raise capital to fund development milestones ## Risks Palisade Bio faces the classic risks of a single-asset clinical-stage biotech: trial failure, regulatory setbacks, and the need for repeated financing before any product revenue exists. Its dependence on a small number of suppliers, CROs, and licensing rights adds operational and legal concentration risk, while Nasdaq listing compliance and capital access remain important financial risks. - **Clinical development failure** [critical] — The company depends on successful Phase 1/2 development of PALI-2108 to create value. - **Regulatory approval and data acceptance risk** [high] — Authorities may not accept foreign trial data or may require additional studies. - **Supply chain and manufacturing concentration** [high] — The company relies on two qualified API suppliers and third-party manufacturers. - **Financing risk** [high] — Development spending exceeds current operating cash generation and requires external funding. - **License agreement dependence** [high] — PALI-2108 rights depend on the Giiant license arrangement and related obligations. - PALI-2108 may fail in clinical development or not reach approval - Patient enrollment and trial timing can delay development milestones - Two-supplier API dependence creates supply and quality risk - License rights from Giiant are critical to the lead program - Additional capital may be needed before commercialization - Nasdaq listing compliance risk if capital markets weaken ## Accounting The most important accounting judgments are accrued research and development expenses, contingent consideration tied to the Giiant license, and fair value changes on warrants or other financing instruments. As a development-stage biotech, reported results are also sensitive to the timing of clinical, manufacturing, and regulatory spending, which can shift materially from quarter to quarter. - **Accrued research and development expenses** — Can shift operating expense timing between quarters - **Contingent consideration liability** — Non-cash remeasurement can affect reported net loss - **Fair value of financing instruments** — Can create volatility in other income/expense - **Quarterly R&D seasonality** — Makes period-to-period comparisons less comparable - Accrued R&D estimates affect trial and vendor expense timing - Contingent consideration valuation can create non-cash gains or losses - Fair value changes on financing-related liabilities may move earnings - Clinical spending is uneven and can distort quarterly comparability - Insurance financing and lease obligations affect liabilities and cash use --- *Last updated: 2026-09-24T11:36:58.663564+00:00*